H.C. Wainwright analyst Robert Burns says the pullback this week in shares of Oric Pharmaceuticals (ORIC) provides an attractive entry point. The firm says the market overreacted to Oric’s metastatic castration-resistant prostate cancer data. Rinzimetostat plus apalutamide “appears to have a significantly better safety profile,” the analyst tells investors in a research note. It reiterates a Buy rating on the shares with a $25 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals should be bought on selloff, says Citi
- Midday Fly By: Nike falls after earnings, Conagra reports mixed results
- Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
- Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
- Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch